Analyst Note
| Aaron Degagne |Narrow-moat Steris reported decent fiscal third-quarter results that met expectations. We had previously updated our model to account for the pending Cantel Medical acquisition, and we are leaving our $181 fair value estimate unchanged. Shares remain fairly valued following the decline in the stock price at market open, which we attribute to Steris’ announcement of CEO Walt Rosebrough’s retirement.